Epizyme Inc

:EPZM   3:59:52 PM EDT
-0.02 (-1.01%)
Other Pre-Announcement, Mergers / Acquisitions

Ipsen To Acquire Epizyme

Published: 06/27/2022 05:13 GMT
Epizyme Inc (EPZM) - To Acquire Epizyme, Expanding Its Portfolio in Oncology.
Transaction Focused on Lead Asset Tazverik (tazemetostat), a First-in-class Ezh2(a )inhibitor Approved in U.S.acquisition to Bolster Ipsen's Growing Oncology Presence and Leverage Its Infrastructure.
To Commence All-cash Tender Offer to Acquire All Outstanding Shares of Epizyme for $1.45 per Share Plus a Contingent Value Right (cvr) of $1.00 per Share.
Transaction is Expected to Be Moderately Dilutive on Ipsen's Core Operating Income Until End of 2024.
Dilutive Impact on 2022 Core Operating Margin Will Be Limited, Given Expected Timing of Transaction.
Initial Results From Phase Iii Randomized Portion of This Study Are Planned to Read Out in 2026.